^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Published date:
11/01/2018
Excerpt:
...study has explored the role of mutation patterns determined by NGS in older AML pts...Pts received one 7+3 course followed by 2 intermediate-dose cytarabine courses…In a multivariate analysis accounting for clinical covariates...SRSF2 (HR=0.64, p=0.03) predicted improved outcome, while FLT3-ITDhigh (HR=2.00, p=0.03), mutations in DNMT3A (HR=1.74, p=0.001), ASXL1 (HR=1.84, p=0.002) and NRAS (HR=1.70, p=0.009), but not RUNX1 or TP53, independently predicted worse OS...
DOI:
10.1182/blood-2018-99-111144
Trial ID: